- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
Poster on Boehringer Ingelheim's clinical trials, Version 2011
During the past decade from 2001 to 2010, Boehringer Ingelheim conducted or sponsored 1,320 studies with 106 substances in 87 countries from all regions of the world. The studies enrolled approximately 1 million patients during this decade, of which nearly 370,000 were in Phase I-IV studies and about 600,000 in PMS studies (post-marketing surveillance). The term ‘patient’ refers here in a wider sense to patients receiving test medication, comparative medications, placebo, marketed medication, or being healthy volunteers. Detailing these numbers by region and clinical phases reveals a broad geographical distribution with emphasis on North America and West Europe.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
